# Migraine Medication Effects on Urinary Symptoms

> **NCT06212661** · — · ENROLLING_BY_INVITATION · sponsor: **The Cleveland Clinic** · enrollment: 200 (estimated)

## Conditions studied

- Overactive Bladder
- Bladder Pain Syndrome
- Migraine Disorders
- Overactive Bladder Syndrome
- Overactive Detrusor
- Migraine
- Interstitial Cystitis

## Interventions

- **DRUG:** Ubrogepant
- **DRUG:** Rimegepant
- **DRUG:** Atogepant
- **DRUG:** Eptinezumab
- **DRUG:** Fremanezumab
- **DRUG:** Galcanezumab
- **DRUG:** Erenumab
- **DRUG:** Botulinum toxin A

## Key facts

- **NCT ID:** NCT06212661
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-04-05
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212661, "Migraine Medication Effects on Urinary Symptoms". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06212661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*